peptide elongation factor 2 has been researched along with Cancer of Esophagus in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Z; Huang, C; Huang, L; Jia, X; Jiang, Y; Laster, KV; Li, H; Li, P; Li, X; Liu, K; Lu, B; Nie, W; Tian, X; Wang, P; Wu, Q; Zhao, D | 1 |
1 other study(ies) available for peptide elongation factor 2 and Cancer of Esophagus
| Article | Year |
|---|---|
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Peptide Elongation Factor 2 | 2023 |